While mass spectrometry–based immunopeptidomics has vastly expanded our ability to characterize the MHC-bound peptidome, distinguishing truly tumor-specific antigens from self-peptides remains difficult, especially for non-reference peptides absent from the canonical proteome. The gene discussed is HLA-C; the disease is neoplasm.